The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
New facility at Pusa Road expands advanced diagnostic, theranostics, and treatment-planning capabilities across oncology, cardiology, neurology, and nephrology
With a PhD in Biochemistry and an executive MBA, she brings nearly two decades of experience in the in vitro diagnostics (IVD) sector
The inspection is now closed, and no regulatory action has been recommended
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
PET sheets are widely recognised for their superior clarity, strength, and barrier properties
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
New manufacturing facility in Mebane to produce at least 40 million laboratory pipette tips per week
AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration
Subscribe To Our Newsletter & Stay Updated
